Additionally, Th17 cells amplified adoptive CTL immunotherapy in one mouse model [34,35], and we have identified one CD4+ Th17 clone from an NPC patient that could inhibit melanoma growth in a NOD/SCID mouse model (unpublished data). Here, CD4 is linked to nasopharyngeal carcinoma.